Bioneeds—A Leading Preclinical CRO providing Integrated Discovery, Development & Regulatory Services to Life Science Companies

Bioneeds is one of the preferred and prominent players in the preclinical space with world-class facilities and expertise in providing end-to-end services. The team is well acquainted with contract research-specific activities, especially in assessing the client’s needs, designing projects to meet desired objectives, and asserting TAT and quality requirements with compliance as a given measure.

The U.S. is a leader in the global pharmaceutical market and the drug development process, and companies are increasingly investing in R&D. The big pharmaceutical companies are partnering with and acquiring assets from smaller biotech companies as a strategic drive. Small- and medium-sized companies are fast advancing their research activities.

California is at the forefront of life sciences research and development of new therapies, and home to several life science clusters that have excellent ecosystems which provide much-needed support to the growth of this sector.

Majority of the pharmaceutical and biotech companies operate in the San Francisco Bay Area and San Diego County, and there is also a growing industry presence in the Los Angeles area, indicating potential expansion into other parts of the state. As one of the prominent pharmaceutical hubs in the U.S., California houses many smaller biotechnology companies that have emerged as leading stakeholders in the development of new therapies, driving innovation and growth. Biotechs have a significant portion of advanced molecules in development across areas including small molecules, monoclonal and polyclonal antibodies, cell and gene therapy, and DNA and RNA therapeutics.

As industry operators continue to develop new therapies and advance biotechnology research, the industry is expected to continue attracting major pharmaceutical companies to the state over the years.

Furthermore, while established pharma companies have an option to build and expand their in-house capabilities and outsource selectively, smaller biotech companies—given their rapid growth and relative lack of development infrastructure—often rely on service providers before they can consider building their own development organizations. As a result, biotech companies are going with the trend of partnering with CROs in India, which can act as both a general contractor and a source of operational innovation.

It is imperative that we need to increase our exposure and visibility in the U.S. market, and more importantly in California, therefore we have chosen to join Biocom California. With a wide range of programs, Biocom California is offering a platform and efficient network of life science companies that will make it easier to engage with pharma and biotech innovators.